Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Herman

Showing results (951-960 of 973) with videos related to

Pageof 98
Sort By:
Cancer|October 5, 2023
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trialsAngela Wangari Walter, Ju-Whei Lee, Joanna M Streck, et al.
Radiology|February 25, 2012
The National CT Colonography Trial: assessment of accuracy in participants 65 years of age and olderC Daniel Johnson, Benjamin A Herman, Mei-Hsiu Chen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 6, 2023
Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical TrialsJoanna M Streck, Ju-Whei Lee, Angela Wangari Walter, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 11, 2016
Fragility of epidermis in newborns, children and adolescentsU Blume-Peytavi, J Tan, D Tennstedt, et al.
Nature Methods|December 30, 2011
A guide to analysis of mouse energy metabolismMatthias H Tschöp, John R Speakman, Jonathan R S Arch, et al.
JAMA Network Open|August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialCynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Science Translational Medicine|October 29, 2025
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthmaSeblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, et al.
The Journal of Infectious Diseases|July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
The Lancet. Infectious Diseases|July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trialGary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.
Pageof 98

Showing results (951-960 of 973) with videos related to

Sort By:
Pageof 98
Cancer|October 5, 2023
The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trialsAngela Wangari Walter, Ju-Whei Lee, Joanna M Streck, et al.
Radiology|February 25, 2012
The National CT Colonography Trial: assessment of accuracy in participants 65 years of age and olderC Daniel Johnson, Benjamin A Herman, Mei-Hsiu Chen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 6, 2023
Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical TrialsJoanna M Streck, Ju-Whei Lee, Angela Wangari Walter, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 11, 2016
Fragility of epidermis in newborns, children and adolescentsU Blume-Peytavi, J Tan, D Tennstedt, et al.
Nature Methods|December 30, 2011
A guide to analysis of mouse energy metabolismMatthias H Tschöp, John R Speakman, Jonathan R S Arch, et al.
JAMA Network Open|August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialCynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Science Translational Medicine|October 29, 2025
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthmaSeblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, et al.
The Journal of Infectious Diseases|July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
The Lancet. Infectious Diseases|July 8, 2022
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trialGary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, et al.
Pageof 98